188 related articles for article (PubMed ID: 25820696)
1. Use of depot medroxyprogesterone acetate and prevalent leiomyoma in young African American women.
Harmon QE; Baird DD
Hum Reprod; 2015 Jun; 30(6):1499-504. PubMed ID: 25820696
[TBL] [Abstract][Full Text] [Related]
2. Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma.
Harmon QE; Patchel SA; Zhao S; Umbach DM; Cooper TE; Baird DD
Obstet Gynecol; 2022 May; 139(5):797-807. PubMed ID: 35576339
[TBL] [Abstract][Full Text] [Related]
3. A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years.
Baird DD; Saldana TM; Shore DL; Hill MC; Schectman JM
Hum Reprod; 2015 Dec; 30(12):2936-44. PubMed ID: 26409013
[TBL] [Abstract][Full Text] [Related]
4. Depot Medroxyprogesterone Acetate Use and Blood Lead Levels in a Cohort of Young Women.
Upson K; Harmon QE; Heffron R; Hall JE; Wise LA; Wegienka G; Tokar EJ; Baird DD
Environ Health Perspect; 2020 Nov; 128(11):117004. PubMed ID: 33206002
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Cyclofem in the treatment of depot medroxyprogesterone acetate induced amenorrhea.
Piya-Anant M; Koetsawang S; Patrasupapong N; Dinchuen P; d'Arcangues C; Piaggio G; Pinol A
Contraception; 1998 Jan; 57(1):23-8. PubMed ID: 9554247
[TBL] [Abstract][Full Text] [Related]
6. Depot medroxyprogesterone acetate use and periodontal health in 15- to 44-year-old US females.
Taichman LS; Sohn W; Kolenic G; Sowers M
J Periodontol; 2012 Aug; 83(8):1008-17. PubMed ID: 22309173
[TBL] [Abstract][Full Text] [Related]
7. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
Vercellini P; De Giorgi O; Oldani S; Cortesi I; Panazza S; Crosignani PG
Am J Obstet Gynecol; 1996 Aug; 175(2):396-401. PubMed ID: 8765259
[TBL] [Abstract][Full Text] [Related]
8. Uterine fibroid incidence and growth in an ultrasound-based, prospective study of young African Americans.
Baird DD; Patchel SA; Saldana TM; Umbach DM; Cooper T; Wegienka G; Harmon QE
Am J Obstet Gynecol; 2020 Sep; 223(3):402.e1-402.e18. PubMed ID: 32105679
[TBL] [Abstract][Full Text] [Related]
9. Cervical cancer risk and use of depot-medroxyprogesterone acetate in Costa Rica.
Oberle MW; Rosero-Bixby L; Irwin KL; Fortney JA; Lee NC; Whatley AS; Bonhomme MG
Int J Epidemiol; 1988 Dec; 17(4):718-23. PubMed ID: 2976059
[TBL] [Abstract][Full Text] [Related]
10. Depot medroxyprogesterone acetate and breast cancer. A review of current knowledge.
Chilvers CE
Drug Saf; 1996 Sep; 15(3):212-8. PubMed ID: 8879975
[TBL] [Abstract][Full Text] [Related]
11. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
[TBL] [Abstract][Full Text] [Related]
12. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density and depot medroxyprogesterone acetate.
Albertazzi P; Bottazzi M; Steel SA
Contraception; 2006 Jun; 73(6):577-83. PubMed ID: 16730487
[TBL] [Abstract][Full Text] [Related]
14. Bone density in long term users of depot medroxyprogesterone acetate.
Gbolade B; Ellis S; Murby B; Randall S; Kirkman R
Br J Obstet Gynaecol; 1998 Jul; 105(7):790-4. PubMed ID: 9692421
[TBL] [Abstract][Full Text] [Related]
15. Douching or Perineal Talc Use and Prevalent Fibroids in Young African American Women.
Wright MA; Moore KR; Upson K; Baird DD; Chin HB
J Womens Health (Larchmt); 2021 Dec; 30(12):1729-1735. PubMed ID: 33667128
[No Abstract] [Full Text] [Related]
16. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
[TBL] [Abstract][Full Text] [Related]
17. Injectable and oral contraceptives and risk of HIV acquisition in women: an analysis of data from the MDP301 trial.
Crook AM; Ford D; Gafos M; Hayes R; Kamali A; Kapiga S; Nunn A; Chisembele M; Ramjee G; Rees H; McCormack S
Hum Reprod; 2014 Aug; 29(8):1810-7. PubMed ID: 24838704
[TBL] [Abstract][Full Text] [Related]
18. Interest in self-administration of subcutaneous depot medroxyprogesterone acetate in the United States.
Upadhyay UD; Zlidar VM; Foster DG
Contraception; 2016 Oct; 94(4):303-13. PubMed ID: 27326938
[TBL] [Abstract][Full Text] [Related]
19. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women.
Orr-Walker BJ; Evans MC; Ames RW; Clearwater JM; Cundy T; Reid IR
Clin Endocrinol (Oxf); 1998 Nov; 49(5):615-8. PubMed ID: 10197077
[TBL] [Abstract][Full Text] [Related]
20. Family History and Uterine Fibroid Development in Black and African American Women.
Langton CR; Harmon QE; Baird DD
JAMA Netw Open; 2024 Apr; 7(4):e244185. PubMed ID: 38568693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
